{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T03:03:09Z","timestamp":1763866989743,"version":"3.45.0"},"reference-count":71,"publisher":"Tech Science Press","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OR"],"published-print":{"date-parts":[[2025]]},"DOI":"10.32604\/or.2024.055154","type":"journal-article","created":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T22:19:03Z","timestamp":1736115543000},"page":"1055-1068","source":"Crossref","is-referenced-by-count":1,"title":["A review on pathobiology of circulating tumour plasma cells: The sine qua non of poor prognosis in plasma cell neoplasms"],"prefix":"10.32604","volume":"33","author":[{"given":"PRATIBHA","family":"SUKU","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"AISHWARYA","family":"DASH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ARAVIND","family":"RADHAKRISHNAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PANKAJ","family":"MALHOTRA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MAN UPDESH SINGH","family":"SACHDEVA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"17807","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024 Sep","journal-title":"Am J Hematol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"e670","DOI":"10.1016\/S2352-3026(22)00165-X","article-title":"The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends","volume":"9","author":"Huang","year":"2022 Sep","journal-title":"Lancet Haematol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"e39698","DOI":"10.1016\/j.heliyon.2024.e39698","article-title":"A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia","volume":"10","author":"Chng","year":"2024 Oct 22","journal-title":"Heliyon"},{"key":"ref4","first-page":"3795","article-title":"Multiple myeloma in the young: insights on prognosis, clinical features and treatment outcome derived from nationwide German registry data and a nested multicenter sample","volume":"109","author":"Kamili","year":"2024 Nov 1","journal-title":"Haematologica"},{"key":"ref5","first-page":"97","article-title":"Outcome in patients with multiple myeloma: does age matter? Cancer Res Stat Treat. 2023 Sep;6(3):446. Tertiary cancer center","volume":"94","author":"Soni","year":"2015 Jan","journal-title":"Ann Hematol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014 Nov","journal-title":"Lancet Oncol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project","volume":"40","author":"D\u2019Agostino","year":"2022 Oct 10","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/ejh.12546","article-title":"Proteasome inhibitors and IMiDs can overcome some high-risk cytogenetics in multiple myeloma but not gain 1q21","volume":"96","author":"Nahi","year":"2016 Jan","journal-title":"Eur J Haematol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma working group","volume":"127","author":"Sonneveld","year":"2016 Jun 16","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"106577","DOI":"10.1016\/j.leukres.2021.106577","article-title":"The frequency and clinico-hematological characteristics of gain (1q21) positive myeloma in an Indian cohort","volume":"105","author":"Panakkal","year":"2021 Jun","journal-title":"Leuk Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"3756","DOI":"10.1182\/blood-2015-03-632075","article-title":"Evidence of an epigenetic origin for high-risk 1q21 copy number aberrations in multiple myeloma","volume":"125","author":"Sawyer","year":"2015 Jun 11","journal-title":"Blood"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.4103\/jcrt.JCRT_1027_19","article-title":"Utility and feasibility of a six-color multiparametric flow cytometry for measurable residual disease analysis in plasma cell myeloma in resource-limited settings with 5-year survival data","volume":"17","author":"Sharma","year":"2021","journal-title":"J Cancer Res Ther"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00109-020-01897-9","article-title":"Liquid biopsies for multiple myeloma in a time of precision medicine","volume":"98","author":"Ferreira","year":"2020 Apr","journal-title":"J Mol Med Berl Ger"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"271","DOI":"10.32604\/or.2023.028668","article-title":"Liquid biopsy and blood-based minimal residual disease evaluation in multiple myeloma","volume":"31","author":"Gozzetti","year":"2023","journal-title":"Oncol Res"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/j.clml.2021.07.032","article-title":"Minimal residual disease in multiple myeloma: potential for blood-based methods to monitor disease","volume":"22","author":"O\u2019Brien","year":"2022 Jan","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3390\/cancers12061499","article-title":"Detection of circulating tumor plasma cells in monoclonal gammopathies: methods, pathogenic role, and clinical implications","volume":"12","author":"Sanoja-Flores","year":"2020 Jun 8","journal-title":"Cancers"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1200\/JCO.22.02114","article-title":"How we manage newly diagnosed multiple myeloma with circulating tumor cells","volume":"41","author":"Van de Donk","year":"2023 Mar 1","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/leu.2014.98","article-title":"Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma","volume":"28","author":"Gonsalves","year":"2014 Oct","journal-title":"Leukemia"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1200\/JCO.22.01040","article-title":"Circulating tumor cell burden as a component of staging in multiple myeloma: ready for prime time?","volume":"40","author":"Chakraborty","year":"2022 Sep 20","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2005-05-1858","article-title":"Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma","volume":"106","author":"Nowakowski","year":"2005 Oct 1","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.1038\/bcj.2016.117","article-title":"Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era","volume":"6","author":"Chakraborty","year":"2016 Dec 16","journal-title":"Blood Cancer J"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/j.bbmt.2018.02.017","article-title":"Circulating plasma cells at the time of collection of autologous PBSC for transplant in multiple myeloma patients is a negative prognostic factor even in the age of post-transplant maintenance therapy","volume":"24","author":"Cowan","year":"2018 Jul","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.3324\/haematol.2017.166629","article-title":"Serial measurements of circulating plasma cells before and after induction therapy have an independent prognostic impact in patients with multiple myeloma undergoing upfront autologous transplantation","volume":"102","author":"Chakraborty","year":"2017 Aug","journal-title":"Haematologica"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/leu.2012.237","article-title":"High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma","volume":"27","author":"Bianchi","year":"2013 Mar","journal-title":"Leukemia"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-018-0153-9","article-title":"Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)","volume":"8","author":"Sanoja-Flores","year":"2018 Nov 19","journal-title":"Blood Cancer J"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/cyto.b.21606","article-title":"Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma","volume":"94","author":"Bae","year":"2018 May","journal-title":"Cytometry B Clin Cytom"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3324\/haematol.11080","article-title":"Report of the European myeloma network on multiparametric flow cytometry in multiple myeloma and related disorders","volume":"93","author":"Rawstron","year":"2008 Mar","journal-title":"Haematologica"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.clml.2013.09.013","article-title":"Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients","volume":"14","author":"Vij","year":"2014 Apr","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41375-019-0588-4","article-title":"Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination","volume":"34","author":"Garc\u00e9s","year":"2020 Feb","journal-title":"Leukemia"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1046\/j.1365-2141.2003.04428.x","article-title":"Bone marrow angiogenesis and circulating plasma cells in multiple myeloma","volume":"122","author":"Kumar","year":"2003 Jul","journal-title":"Br J Haematol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/bjh.13484","article-title":"Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics","volume":"170","author":"Vagnoni","year":"2015 Aug","journal-title":"Br J Haematol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/blood-2012-01-379024","article-title":"Myeloma as a model for the process of metastasis: implications for therapy","volume":"120","author":"Ghobrial","year":"2012 Jul 5","journal-title":"Blood"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"363ra147","DOI":"10.1126\/scitranslmed.aac7037","article-title":"Genetic interrogation of circulating multiple myeloma cells at single-cell resolution","volume":"8","author":"Lohr","year":"2016 Nov 2","journal-title":"Sci Transl Med"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.bbmt.2013.04.025","article-title":"Molecular monitoring of minimal residual disease in the peripheral blood of patients with multiple myeloma","volume":"19","author":"Korthals","year":"2013 Jul","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"5782","DOI":"10.1182\/blood-2011-09-380410","article-title":"Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features","volume":"119","author":"Azab","year":"2012 Jun 14","journal-title":"Blood"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2141.1994.tb04908.x","article-title":"Detection of peripheral blood plasma cells as a predictor of disease course in patients with smouldering multiple myeloma","volume":"87","author":"Witzig","year":"1994 Jun","journal-title":"Br J Haematol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1080\/10428190500051448","article-title":"Extracellular matrix in bone marrow can mediate drug resistance in myeloma","volume":"46","author":"Vincent","year":"2005 Jun","journal-title":"Leuk Lymphoma"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/cancers13020217","article-title":"The role of tumor microenvironment in multiple myeloma development and progression","volume":"13","author":"Garc\u00eda-Ortiz","year":"2021 Jan 9","journal-title":"Cancers"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1182\/blood.V97.2.346","article-title":"Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1\/fibronectin and VCAM-1","volume":"97","author":"Sanz-Rodr\u00edguez","year":"2001 Jan 15","journal-title":"Blood"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1111\/febs.16385","article-title":"Dynamic organization of the bone marrow plasma cell niche","volume":"289","author":"Aaron","year":"2022 Jul","journal-title":"FEBS J"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1084\/jem.20041185","article-title":"The role of CXCR4 in maintaining peripheral B cell compartments and humoral immunity","volume":"200","author":"Nie","year":"2004 Nov 1","journal-title":"J Exp Med"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3389\/fimmu.2019.00788","article-title":"In the right place, at the right time: spatiotemporal conditions determining plasma cell survival and function","volume":"10","author":"Lindquist","year":"2019","journal-title":"Front Immunol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1146\/annurev-pathol-011110-130249","article-title":"Pathogenesis of myeloma","volume":"6","author":"Anderson","year":"2011","journal-title":"Annu Rev Pathol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1182\/blood-2011-07-368050","article-title":"P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment","volume":"119","author":"Azab","year":"2012 Feb 9","journal-title":"Blood"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/leu.2015.332","volume":"30","author":"Mart\u00ednez-Moreno","year":"2016 Apr","journal-title":"Leukemia"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2013.148","article-title":"Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib","volume":"27","author":"Stessman","year":"2013 Oct","journal-title":"Leukemia"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"6202","DOI":"10.1182\/blood-2010-06-292243","article-title":"Integrin \u03b27-mediated regulation of multiple myeloma cell adhesion, migration, and invasion","volume":"117","author":"Neri","year":"2011 Jun 9","journal-title":"Blood"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2141.2011.08864.x","article-title":"The selective adhesion molecule inhibitor Natalizumab decreases multiple myeloma cell growth in the bone marrow microenvironment: therapeutic implications","volume":"155","author":"Podar","year":"2011 Nov","journal-title":"Br J Haematol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1158\/0008-5472.CAN-17-0115","article-title":"HIF-2\u03b1 promotes dissemination of plasma cells in multiple myeloma by regulating CXCL12\/CXCR4 and CCR1","volume":"77","author":"Vandyke","year":"2017 Oct 15","journal-title":"Cancer Res"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"108733","DOI":"10.1016\/j.celrep.2021.108733","article-title":"Plasma cell dynamics in the bone marrow niche","volume":"34","author":"Benet","year":"2021 Feb 9","journal-title":"Cell Rep"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.celrep.2017.03.025","article-title":"The mutational landscape of circulating tumor cells in multiple myeloma","volume":"19","author":"Mishima","year":"2017 Apr 4","journal-title":"Cell Rep"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/imr.12011","article-title":"The establishment of the plasma cell survival niche in the bone marrow","volume":"251","author":"Chu","year":"2013 Jan","journal-title":"Immunol Rev"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.1200\/JCO.2005.03.159","article-title":"Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance","volume":"23","author":"Kumar","year":"2005 Aug 20","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"101025","DOI":"10.1016\/j.currproblcancer.2023.101025","article-title":"Detection of circulating normal and tumor plasma cells in newly diagnosed patients of multiple myeloma and their associations with clinical and laboratory parameters","volume":"48","author":"Gupta","year":"2023 Nov 9","journal-title":"Curr Probl Cancer"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1002\/hem3.63","article-title":"Circulating tumor plasma cells and peripheral blood measurable residual disease assessment in multiple myeloma patients not planned for upfront transplant","volume":"8","author":"Tembhare","year":"2024 Apr","journal-title":"HemaSphere"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"55","DOI":"10.5045\/br.2017.52.1.55","article-title":"Characterization of clonal immunoglobulin heavy (IGH) V-D-J gene rearrangements and the complementarity-determining region in South Indian patients with precursor B-cell acute lymphoblastic leukemia","volume":"52","author":"Sudhakar","year":"2017 Mar","journal-title":"Blood Res"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma working group","volume":"121","year":"2003 Jun","journal-title":"Br J Haematol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41408-024-01113-8","article-title":"Real-life sensitivity of flow cytometry minimal residual disease assessment for plasma cell neoplasms","volume":"14","author":"Jevremovic","year":"2024 Jul 31","journal-title":"Blood Cancer J"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41408-020-00377-0","article-title":"Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma","volume":"10","author":"Medina","year":"2020 Oct 30","journal-title":"Blood Cancer J"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.3390\/cancers12082322","article-title":"Comparison of NGS and MFC methods: key metrics in multiple myeloma MRD assessment","volume":"12","author":"Kriegsmann","year":"2020 Aug 18","journal-title":"Cancers"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"102016","DOI":"10.1016\/j.eclinm.2023.102016","article-title":"Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing","volume":"60","author":"Oliva","year":"2023 Jun","journal-title":"eClinicalMedicine"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/bjh.15003","article-title":"Enumeration and characterization of circulating multiple myeloma cells in patients with plasma cell disorders","volume":"180","author":"Foulk","year":"2018 Jan","journal-title":"Br J Haematol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/ajh.25709","article-title":"Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells","volume":"95","author":"Gonsalves","year":"2020 Mar","journal-title":"Am J Hematol"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1083053","DOI":"10.3389\/fonc.2023.1083053","article-title":"High-risk multiple myeloma predicted by circulating plasma cells and its genetic characteristics","volume":"13","author":"Xia","year":"2023","journal-title":"Front Oncol"},{"key":"ref65","first-page":"510","article-title":"Prognostic value of circulating clonal plasma cells in newly diagnosed multiple myeloma","volume":"26","author":"Han","year":"2021 Dec","journal-title":"Hematol Amst Neth"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/bjh.17118","article-title":"The detection of circulating plasma cells may improve the Revised International Staging System (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma","volume":"193","author":"Galieni","year":"2021 May","journal-title":"Br J Haematol"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1200\/JCO.21.01365","article-title":"Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma","volume":"40","author":"Garc\u00e9s","year":"2022 Sep 20","journal-title":"J Clin Oncol"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.21.01393","article-title":"High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma","volume":"40","author":"Bertamini","year":"2022 Sep 20","journal-title":"J Clin Oncol"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1002\/ajh.27414","article-title":"Low circulating tumor cell levels correlate with favorable outcomes and distinct biological features in multiple myeloma","volume":"99","author":"Kostopoulos","year":"2024 Oct","journal-title":"Am J Hematol"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jgo.2020.12.001","article-title":"Transplant-ineligible newly diagnosed multiple myeloma: current and future approaches to clinical care: a young international society of geriatric oncology review paper","volume":"12","author":"Grant","year":"2020 Dec 17","journal-title":"J Geriatr Oncol"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1182\/blood-2005-08-3398","article-title":"Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification system","volume":"107","author":"Dingli","year":"2006 Apr 15","journal-title":"Blood"}],"container-title":["Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.techscience.cn\/files\/or\/2025\/TSP_OR-33-5\/OncolRes-33-05-55154\/OncolRes-33-55154.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T01:09:55Z","timestamp":1763341795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v33n5\/60613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":71,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.32604\/or.2024.055154","relation":{},"ISSN":["1555-3906"],"issn-type":[{"type":"electronic","value":"1555-3906"}],"subject":[],"published":{"date-parts":[[2025]]}}}